A Study of BL-B01D1, SI-B003 and BL-B01D1+SI-B003 in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid Tumor
A phase 2 trial of Izalontamab brengitecan in head and neck squamous cell carcinoma, run by Sichuan Baili Pharmaceutical Co., Ltd., now recruiting.
Overview
A Study of BL-B01D1, SI-B003 and BL-B01D1+SI-B003 in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid Tumors is a phase 2 interventional study registered as NCT06006169 by Sichuan Baili Pharmaceutical Co., Ltd., with 186 participants planned, started 2023-10-20 and due to reach its primary completion in 2026-12. Interventions recorded: BL-B01D1, SI-B003. Conditions listed: Head and Neck Squamous Cell Carcinoma. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid Tumors
Shares Izalontamab brengitecan, SystImmune / Sichuan Biokin, Head and neck squamous cell carcinoma.
- TrialA Study of SI-B003, BL-B01D1+SI-B003 and BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Esophageal Cancer, Gastric
Shares Izalontamab brengitecan, SystImmune / Sichuan Biokin.
- TrialA Study of BL-B01D1, SI-B003 and BL-B01D1+SI-B003 in Patients With Extensive Stage Small Cell Lung Cancer
Shares Izalontamab brengitecan, SystImmune / Sichuan Biokin.
- TrialA Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Extensive-stage Small Cell Lung Cancer
Shares Izalontamab brengitecan, SystImmune / Sichuan Biokin.
- TrialA Study Comparing BL-B01D1 With the Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Recurrent Epithelial Ovarian Cancer(PANK
Shares Izalontamab brengitecan, SystImmune / Sichuan Biokin.
- TrialA Study of BL-B01D1, SI-B003 and BL-B01D1+SI-B003 in Patients With Recurrent or Metastatic Cervical Cancer and Other Gynecological Malignancies
Shares Izalontamab brengitecan, SystImmune / Sichuan Biokin.
- TrialA Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Chordoma
Shares Izalontamab brengitecan, SystImmune / Sichuan Biokin.
- TrialA Study Comparing BL-B01D1 With Topotecan in Patients With Recurrent Small Cell Lung Cancer(PANKU-Lung03)
Shares Izalontamab brengitecan, SystImmune / Sichuan Biokin.